TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

More documents

Recommendations

Info

29B.56 Rodriguez M et al. Failure of low dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients. Clin Infect Dis 2004;38:e76-8. 29B.57 Pneumocystis jiroveci (formerly Pneumocystis carinii). Am J Transplant 2004;4(suppl. 10):135-41. 29B.58 Derouin F et al. Prevention of toxoplasmosis in transplant patients. Clin Microbiol Infect 2008;14: 1089-101. 29B.59 Kun H et al. Transmission of Trypanosoma cruzi by heart transplantation. Clin Infect Dis 2009;48: 1534-40. 29B.60 Bern C et al. Evaluation and treatment of Chagas disease in the United States: a systematic review. J Am Med Assoc 2007;298:2171-81. 29B.61 Altclas JD et al. Organ transplantation and Chagas disease. J Am Med Assoc 2008;299:1134-5. 29B.62 Bestetti RB et al. A systematic review of studies on heart transplantation for patients with end-stage Chagas‘ heart disease. J Cardiac Fail 2009;15:249-55. 29B.63 Blair JE. Approach to the solid organ transplant patient with latent infection and disease caused by Coccidioides species. Curr Opin Infect Dis 2008;21:415-20. 29B.64 Soave R. Prophylaxis strategies for solid organ transplantation. Clin Infect Dis 2001;33(suppl. 1): S26-31. 29B.65 Parasitic infections. Am J Transplant 2004;4(suppl. 10):142-55. 29B.66 Fungal infections. Am J Transplant 2004;4(suppl. 10):110-34. 29B.67 Cytomegalovirus. Am J Transplant 2004;4(suppl. 10):51-8. 29B.68 Avery RK. Prophylactic strategies before solid organ transplantation. Curr Opin Infect Dis 2004;17: 353-6. 29B.69 Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007;357:2601-14. 29B.70 Martín-Dávila M et al. Transmission of tropical and geographically restricted infections during solidorgan transplantation. Clin Microbiol Rev 2008;21:60-96. 29B.71 Sun HY et al. Pharmacotherapy of post-transplant viral infections. Expert Opin Pharmacother 2008; 9:2409-21. 29B.72 Bouza E et al. Fever of unknown origin in solid organ transplant recipients. Infect Dis Clin North Am 2007;21:1033-54. 29B.73 Hanson K et al. Strategies for the prevention of infection after solid organ transplantation. Expert Rev Anti Infect Ther 2006;4:837-52. 29B.74 Kotton CN. Zoonoses in solid-organ and hematopoietic stem cell transplant recipients. Clin Infect Dis 2007;44:857-66. 29B.75 Tomblyn M et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective Biol Blood Marrow Transplant 2009;15:1143-238. 29B.76 Castagnola E et al. Management of bacteremia in patients undergoing hematopoietic stem cell transplantation. Expert Rev Anti Infect Ther 2009;7:607-21. 30A.1 Provan D et al. Prescribing intravenous immunoglobulin: summary of Department of Health guidelines. Br Med J 2008;337:990-2. 31A.1 Kampf G et al. Epidemiologic background of hand hygiene and evaluation of the most important agents for scrubs and rubs. Clin Microbiol Rev 2004;17:863-93. 31A.2 Boyce JM et al. Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the ICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol 2002;23(suppl.):S3-40. 31A.3 Centers for Disease Control and Prevention (CDC). Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the ICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Morb Mortal Wkly Rep 2002;52(RR-16):1-45. 31A.4 Tanner J et al. Surgical hand antisepsis to reduce surgical site infection. Cochrane Database Syst Rev 2008;1:CD004288. 31A.5 Darouiche RO et al. Chlorhexidine-alcohol versus povidone-iodine for surgical-site antisepsis. N Engl J Med 2010;362:18-26. 31A.6 Dettenkofer M et al. Hospital disinfection: efficacy and safety issues. Curr Opin Infect Dis 2005;18: 320-5. 31A.7 Cozad A et all. Disinfection and the prevention of infectious disease. Am J Infect Control 2003;31: 243-53. 31A.8 Daschner F et al. Disinfection and the prevention of infectious disease: No adverse effects? Am J Infect Control 2004;32:224-5. 31A.9 Rutala WA et al. Disinfection and sterilization in health care facilities: what clinicians need to know. Clin Infect Dis 2004;39:702-9. 31A.10 Hota B. Contamination, disinfection and cross colonization: are hospital surfaces reservoirs for nosocomial infection? Clin Infect Dis 2004;39:1182-9. 31A.11 Rutala WA et al. The benefits of surface disinfection. Am J Infect Control 2004;32:226-31. 31B.1 McDonnell G et al. Antiseptics and disinfectants: activity, action and resistance. Clin Microbiol Rev 1999;12:147-79. 31B.2 Sheldon AT. Antiseptic ―resistance‖: real or perceived threat? Clin Infect Dis 2005;40:1650-6. 31B.3 Russell AD. Bacterial adaptation and resistance to antiseptics, disinfectants and preservatives is not a new phenomenon. J Hosp Infect 2004;57:97-104. 32.1 World Health Organization. WHO model formulary 2008. Available at: http://www.who.int/selection _medicines/list/WMF2008.pdf. Accessed on October 19 th 2010. 32.2 World Health Organization. WHO model formulary for children 2010. Available at: http://www.who.int/ selection_medicines/list/WMFc_2010.pdf. Accessed on October 19 th 2010. 32.3 Green IT et al. Antibiotic, antifungal, and antiviral dosage in hepatic impairment. LA Health Syst Pharm 2009;18(4):4-6. 32.4 Wyles DL et al. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin Infect Dis 2005;40:174-81.
33A.1 Kearney BP et al. The penetration of anti-infectives into the central nervous system. Neurol Clin 1999;17:883-900. 33A.2 Täuber MG et al. General principles of therapy of pyogenic meningitis. Infect Dis Clin North Am 1990;4:661-76. 33A.3 Andes DR et al. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect Dis Clin North Am 1999;13:595-618. 33A.4 Sinner SW et al. Antimicrobial agents in the treatment of bacterial meningitis. Infect Dis Clin North Am 2004;18:581-602. 33A.5 Markantonis SL et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother 2009;53:4907-10. 33A.6 Kanellakopoulou K et al. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. J Antimicrob Chemother 2008;61:1328-31. 33A.7 Black KE et al. Fungal infections of the CNS. Treatment strategies for the immunocompromised patient. CNS Drugs 2007;21:293-318. 33A.8 Kethireddy S et al. CNS pharmacokinetics of antifungal agents. Expert Opin Drug Metab Toxicol 2007;3:571-81. 33B.1 Letendre S et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008;65:65-70. 33B.2 Letendre SL et al. Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disor- ders. Ann Neurol 2004;56;416-23. 33B.3 McGee B et al. HIV pharmacology: barriers to the eradication of HIV from the CNS. HIV Clin Trials 2006;7:142-53. 34.1 Piraino B et al. Peritoneal dialysis-related infections. Recommendations: 2005 update. Perit Dial Int 2005;25:107-31. 34.2 de Vin F et al. Intraperitoneal administration of drugs in peritoneal dialysis patients: a review of compatibility and guidance for clinical use. Perit Dial Int 2009;29:5-15. 36.1 Committee on Drugs of the American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776-89. 36.2 Nahum GG et al. Antibiotic use in pregnancy and lactation. What is and is not known about teratogenic and toxic risks. Obstet Gynecol 2006;107:1120-38. 36.3 Ilett KF et al. Drug Use and breastfeeding. Expert Opin Drug Saf 2005;4:745-68. 36.4 Bar-Oz B et al. Use of antibiotic and analgesic drugs during lactation. Drug Saf 2003;26:925-35. 36.5 Hale TW. Maternal medications during breastfeeding. Clin Obstet Gynecol 2004;47:696-711. 37A.1 Win PH et al. Rapid intravenous cephalosporin desensitization. J Allergy Clin Immunol 2005;116: 225-8. 37B.1 Matz J et al. Oral desensitization to rifampin and ethambutol in mycobacterial disease. Am J Respir Crit Care Med 1994;149:815-7. 37C.1 Weiss ME. Evaluation and treatment of patients with prior reactions to �-lactam antibiotics. Curr Clin Top Infect Dis 1993;13:131-45. 37C.2 Turvey SE et al. Antibiotic desensitization for the allergic patient: 5 years of experience and practice. Ann Allergy Asthma Immunol 2004;92:426-32. 37C.3 Castells M. Desensitization for drug allergy. Curr Opin Allergy Clin Immunol 2006;6:476-81. 37D.1 Matz J et al. Oral desensitization to rifampin and ethambutol in mycobacterial disease. Am J Respir Crit Care Med 1994;149:815-7. 37E.1 Tenant-Flowers M et al. Sulphadiazine desensitization in patients with AIDS and cerebral toxoplasmosis. AIDS 1991;5:311-5. 37F.1 Para MF et al. Reduced toxicity with gradual initiation of trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis carinii pneumonia: AIDS Clinical Trials Group 268. J Acquir Immune Defic Syndr 2000;24:337-43. 37F.2 Tilles SA. Practical issues in the management of hypersensitivity reactions: sulfonamides. South Med J 2001;94:817-24. 37F.3 Gluckstein D et al. Rapid oral desensitization to trimethoprim-sulfamethoxazole (TMP-SMZ): use in prophylaxis for Pneumocystis carinii pneumonia in patients with AIDS who were pre-viously intolerant to TMP-SMZ. Clin Infect Dis 1995;20:849-53. TABLE 39B ABBREVIATIONS OF JOURNALS REFERRED TO IN THE GUIDE Acta Clin Belg Acta Clinica Belgica Acta Derm Venereol Acta Dermato-Venereologica Acta Ophthalmol Acta Ophthalmologica Acta Trop Acta Tropica Adv Parasitol Advances in Parasitology Adv Skin Wound Care Advances in Skin and Wound Care Aesthetic Plast Surg Aesthetic Plastic Surgery AIDS Acquired Immune Deficiency Syndrome
Page 1 and 2:
TABLE 39A LIST OF PUBLICATIONS REFE
Page 3 and 4:
1.89 Laupland KB. Vascular and para
Page 5 and 6:
of NICE guidance. Br Med J 2008;337
Page 7 and 8:
tions à Clostridium difficile dans
Page 9 and 10:
sis of placebo-controlled trials. C
Page 11 and 12:
1.446 Centers for Disease Control a
Page 13 and 14:
1.532 Olaison L et al. Enterococcal
Page 15 and 16:
1.615 Muder RR et al. Isolation of
Page 17 and 18:
2005;352:865-74. 1.699 Brown-Elliot
Page 19 and 20:
2009;123:1108-15. 1.782 Ellis MW. A
Page 21 and 22:
1.873 Korting HC et al. Current top
Page 23 and 24:
1.970 Thomas RJ et al. Current mana
Page 25 and 26:
of severe respiratory failure. Clin
Page 27 and 28:
1.1166 Aldape MJ et al. Clostridium
Page 29 and 30:
2A.36 Wormser GP. Early Lyme diseas
Page 31 and 32:
test methodology. Eur J Clin Microb
Page 33 and 34:
2B.39 Cookson BD et al. Guidelines
Page 35 and 36:
2009;15(suppl. 3):7-11. 2B.115 Jaco
Page 37 and 38:
82. 4A.87 de Smet AM et al. Deconta
Page 39 and 40:
after acute pyelonephritis: a multi
Page 41 and 42:
for intensive care patients with no
Page 43 and 44:
among hospitalized patients. Clin I
Page 45 and 46:
Ther 2006;4:947-52. 5D.1 Demirovic
Page 47 and 48:
7.38 Meersseman W et al. Invasive a
Page 49 and 50: 7.121 Walsh TJ et al. All catheter
Page 51 and 52: nail onychomycosis. J Eur Acad Derm
Page 53 and 54: 2006. Clin Infect Dis 2006;43:1580-
Page 55 and 56: 9A.5 Andes D. Pharmacokinetics and
Page 57 and 58: factor and other newly approved bio
Page 59 and 60: cument E.DEF 8.1). Report of the Su
Page 61 and 62: Br J Dermatol 2004;151:1096-100. 11
Page 63 and 64: new prediction equation. Ann Intern
Page 65 and 66: 14A.93 Sundar S et al. New treatmen
Page 67 and 68: eview. Obstet Gynecol 2005;105:857-
Page 69 and 70: 2003;1:471-82. 14A.278 Walker MD et
Page 71 and 72: 14B.4 Checkley AM et al. Eosinophil
Page 73 and 74: 18.12 Panel on Antiretroviral Thera
Page 75 and 76: 18.91 Lesho E. Evidence base for us
Page 77 and 78: tients. J Antimicrob Chemother 2009
Page 79 and 80: duct characteristics. Available at:
Page 81 and 82: _Product_Information/human/000338/W
Page 83 and 84: 114:23-33. 21.80 Jabs DA et al. Fom
Page 85 and 86: North Am 2006;20:155-74. 21.176 Nas
Page 87 and 88: 1995;14:827-32. 21.264 Scott LL. Pe
Page 89 and 90: 21.358 Calabrese LH et al. Viral Ar
Page 91 and 92: 24. 21.452 Jeha LE et al. Long term
Page 93 and 94: induced functional androgen deficie
Page 95 and 96: 25A.27 Conseil Supérieur de la San
Page 97 and 98: product characteristics. Available
Page 99: mortality after kidney transplantat
Page 103 and 104: Clin Plast Surg Clinics in Plastic
Page 105 and 106: Mycopathologia Mycopathologia Mycos
show all

TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?